Background: Compared with general population mortality rates are 10-20 times higher among patients with end stage renal disease, with 50% of this excess burden being attributable to cardiovascular disease. This excess risk is not entirely explained by elevation of traditional risk factors. Elevation of several Non-traditional risk factors associated with an increased risk for cardiovascular disease in CKD and haemodialysis dependent patients.
Introduction
Mortality rates are 10-20 times higher among patients with end-stage renal disease, compared with the general population, with 50% of this excess burden being attributable to cardiovascular disease. 1 Though the prevalence of traditional risk factors for cardiovascular disease, including diabetes and hypertension, are common among patients with CKD and may partially account for the excess risk for cardiovascular disease among these patients. 2 However, several prospective cohort studies indicate that, this excess risk is not entirely explained by elevated traditional risk factors. 3 Non-traditional risk factor such as elevated level of homocysteine, fibrinogen, Factor VII, C-reactive protein has been associated with an increased risk for cardiovascular disease. 3 Traditional risk factors are limited predictors of cardiovascular morbidity and mortality in ESRD. Nontraditional risk factors e.g. hyperhomocysteinemia has been found more commonly than traditional risk factors in ESRD patients on haemodialysis and is contributing independently to excess incidence of fatal and non-fatal cardiovascular outcomes. 4 Therefore, much recent interest has focused on non -traditional risk factors, as promoters of atherosclerosis. Several non-traditional factors, such as hyperhomocystenemia, anaemia, thrombogenic factors elevated fibrinogen and factor VII and elevated inflammatory markers especially elevated fibrinogen, factor VII, and CRP are associated with cardiovascular events in CKD patients. 5 
Material and methods:
This case control study was conducted in Department of Nephrology of Dhaka Medical College done during the period of Oct"2007-Sep 2008. The study protocol was reviewed and approved by the Dhaka medical college Ethics committee. Study populations were selected by specific selection criteria. Of the total 96 subjects, 48 cases of had CKD who never received haemodialysis or peritoneal dialysis treatment and 22 cases were haemodialysis dependent patient and 26 healthy non-hypertensive controls. All of the selected patients were submitted to clinical and physical evaluation and laboratory investigation done to identify cardiovascular disease by ECG, Echocardiography, stress test or angiography and also identify cardiovascular risk factors (both traditional and non-traditional risk factors). All patients gave informed written consent.. Blood sample were drawn in the fasting state and resting for at least 10 minutes before blood sampling. Venous blood collected from the right antecubital vein of CKD patients and healthy controls with minimal stasis and without frothing using standard equipment. In haemodialysis patients the arterio-venous fistula punctured with an arteriovenous needle immediately before the start of haemodialysis. 1 ml EDTA blood used for complete blood count. 1.8ml (9 volumes) blood mixed with 0.2 ml sodium citrate (1 volume), centrifuged at 2000 g for 20 min. Separated plasma was , aliquoted and stored at -70 o C until used for assay of factor vii activity and plasma fibrinogen level. 2 ml of serum was separated, aliquoted and stored at -7 0 C until used for assay of total serum homocysteine , C-reactive protein , serum lipid profile, and kidney function tests including creatinine and urea. All investigations were done in single specialized diagnostic center in Dhaka. Data was analyzed using the statistical package SPSS 11.5 version.
Results:
Total ninety six (96) participants were included in the study. The mean age of 46.75± 10.20 SD years, Forty eight (48) patients, of which 31(64.6%) male and 17 (35.4%) female were chronic kidney disease of different stages mostly stage III-V and twenty two (22) patients, of which 6 (23.3%) female and 16 (72.7%) male, were from maintenance haemodialysis and twenty six (26) person 17(65.38%) male and 9 (34.62%) female were non-hypertensive, non-diabetic, control subject. (Fig-1 ). 
Fig-1: Bar diagram showing sex distribution among different group

Comparison between normal control group and Non-dialysis, Hemodialysis dependent groups:
Comparison between normal control group and non-dialysis CKD groups and haemodialysis dependent groups by one way analysis ANOVA revealed there were significant difference between groups in non-traditional cardiovascular risk factors. Table II shows Fibrinogen (p-<.001), CRP (p-.002), factor VII (p<.001) and hemoglobin (p<.001), homocysteine (<.001) were significantly different between control groups and nondialysis and hemodialysis groups.
Comparison between normal control group and non-dialysis CKD group:
In comparison between normal control group and nondialysis CKD group's with age and sex match, homocysteine, fibrinogen, CRP, factor VII and hemoglobin level were significantly difference between groups. (Table -III) . cardiovascular disease. A community based cohort showed that the prevalence of all the major traditional cardiovascular risk factors was significantly higher in patients with even mild renal failure (serum creatinine >1.5mg/dl) than in those with normal renal function. 9 Several prospective epidemiologic studies have identified a positive association between plasma fibrinogen level and risk for cardiovascular disease. An increase in plasma fibrinogen levels of approximately 1 gm/L corresponds to a 1.8 fold increase in the risk for coronary heart disease. 10 A few clinical studies have suggested that fibrinogen levels are higher in patients with CKD and treated with haemodialysis or peritoneal dialysis. Irish examined plasma fibrinogen levels among 126 patients with chronic kidney failure and 31 healthy controls. Mean levels of plasma fibrinogen were significantly increased in patients with chronic kidney failure compaired with those in the control groups (12.38 µmol/L vs. 7. 88 µmol/L; p<0.001). 11 Muntner P et al in 2004 showed elevated levels of plasma fibrinogen in a large representative sample of patient with chronic kidney disease. Fibribinogen is a classical acute phase reactant protein and is an independent predictor of cardiovascular events. The risk of myocardial infarction (MI) almost doubles if fibrinogen level exceeds 300 mg/dl. 1 In our current study, we documented elevated level of plasma fibrinogen in chronic kidney disease and haemodilysis dependent patients in respect to normal control group. Mean fibrinogen level was 264.10±67.81mg/dl, 259.59±60.92mg/dl and 180.25±40.64mg/ dl in non-dialysis CKD and haemodialysis and normal control group. In comparison to normal control population, fibrinogen is significantly higher in non-dialysis CKD (p-.001) and haemodialysis dependent patients (p-<.001).
Hyper-homocysteinaemia revealed a strong independent atherogenic risk factor in CKD patients, as already observed in the general population. Important finding of our study was increased level of plasma homocystein level in CKD and haemodialysis dependent patient in comparison to normal control groups. Plasma homocysteine level increased in those patients with cardiovascular disease than those not having cardiovascular disease in both non-dialysis CKD and haemodialysis groups. Hyper-homocysteinaemia has been found in adult patients with ESRD and predialysis CKD. 12 Elevated Homocysteine concentrations have been associated with an increased risk of atherothrombotic events in adults. Risk factors analysis showed a significant association of hyperhomocysteinemia with premature vascular disease, even after adjustment for other atherogenic factors, including serum cholesterol, hypertension, or cigarette smoking, supporting the view that hyperhomocysteinemia is an independent risk factor for atherosclerosis. 13 In chronic kidney disease, atherosclerosis is a major problem which determines the prognosis of chronic uraemic patients to a great extent, either dialyzed or not. 14 In this study mean homocysteine concentration was 15.38 ± 5.06µmol/L, 22.99 ± 8.70µmol/L and 23.76 ± 9.15µmol/L in control, non-dialysis CKD and haemodialysis dependent patient respectively. In compared to normal control plasma homocysteine was significantly higher in CKD (p-.001) and haemodialysis dependent patient (p<.001).
C-reactive protein is an acute phase protein and a predictor of cardiovascular mortality which have been shown in metaanalysis of several prospective studies. 15, 16 ESRD patients have also demonstrated an association between elevated CRP levels with increased cardiovascular mortality. 17 Several studies also demonstrate that CRP is elevated in a significant proportion of ESRD patients without any apparent reason. In a prospective cohort analysis of haemodialysis patients, Zimmermann et al also showed cardiovascular mortality was higher in patients with elevated CRP. 18 Two cross sectional studies demonstrated that elevated CRP levels were associated with surrogate markers for atherosclerotic vascular disease in both haemodialysis dependent patients and nondialysis CKD patients. 19 In current study, CRP level were elevated in patients with CKD and haemodialysis patients. Mean CRP level 3.90 ± 1.03mg/L, 17.31 ± 18.42 mg/dl and 52.59±82.16 mg/L in normal control group, CKD non-dialysis and haemodialysis dependent patients respectively. CRP was significantly higher in CKD (p-.004) and haemodialysis dependent patient (p-.001) in compared to normal control group.
Erythropoietin is produced in the kidney, and anaemia resulting from a deficiency of erythropoietin is present in the majority of patients with ESRD. Smaller reductions in hemoglobin occur in mild to moderate renal impairment. Anemia induced cardiac abnormalities in CKD patients is a very frequent complication. There is increasing evidence that early and complete anemia correction may slow down the progression of CKD thus preventing cardiovascular and overall morbidity and improve survival in dialysis population. A number of observational studies have shown that it inversely correlates with residual renal function, yet its prevalence is already high during the earlier stage of CKD. 6 Evidence suggests that low hemoglobin is a risk factor for cardiovascular disease. A recent analysis of the ARIC (Atherosclerosis Risk In Communities) study data found a 40% increased risk of CVD in subjects with anaemia compared with patients with normal hemoglobin. 20 Low hemoglobin also increases the risk of death in patients with heart failure independent of renal failure. In this study hemoglobin level was low and mean hemoglobin level 13.85 ±1.59 gm/dl, 9.46± 1.87 mg/dl and 8.08±1.94 gm/dl in normal control group, non-dialysis CKD and haemodialysis dependent patients respectively. In comparison to normal control groups, haemoglobin is significantly low in haemodialys (p<.001) and non-dialysis CKD (P-<.001).
In general population, activation of blood coagulation is associated with hyperlipidaemia via an increase in mass and activity of factor VII. 21 An elevated Factor VII activity level has been shown to be related to increased risk of myocardial infarcion. 20 Northwick Park Heart Study also suggested that elevated activity of factor VII, measured as factor VII coagulant activity (VIIc), was predictive of future CVD events in men. 22 Though Ashley et al showed no significant difference in factor VIIc between patients with cardiovascular disease and those without cardiovascular disease, but were able to show that patients on haemodialysis and non-dialysis CKD have increased factor VII antigen and VIIc when compared with healthy controls. 23 In our study we documented that factor VII activity increased in CKD nondialysis patients and haemodialysis patient in compared to normal control group. Mean level of factor VII 94.18 ± 12.66%, 106.18 ±14.64% and 103.97±14.41% was found in normal control group, haemodialysis dependent patients and nondialysis CKD patients respectively. Factor VII activity is significantly higher in non -dialysis CKD (p-<.001) and haemodialysis dependent patients (p-.001).
